Clinical Trials Logo
  1. Home
  2. Gastrointestinal Stromal Tumor
  3. NCT03493152
  4. Details
NCT03493152 Clinical Trial

Expanded Access to Everolimus, for an Individual Patient With GIST (Gastrointestinal Stromal Tumors)(CTMS#18-0019)

Gastrointestinal Stromal Tumor Clinical Trial

Official title:
Expanded Access to Everolimus, for an Individual Patient With GIST (Gastrointestinal Stromal Tumors)(CTMS#18-0019)

Clinical Trial Details — Status: Temporarily not available

Administrative data
NCT number NCT03493152
Other study ID # CTMS# 18-0019
Secondary ID HSC20180169T
Status Temporarily not available
Phase
First received
Last updated

Study information
Verified date June 2023
Source The University of Texas Health Science Center at San Antonio
Contact n/a
Is FDA regulated No
Health authority
Study type Expanded Access

Clinical Trial Summary

Single patient treatment with everolimus.

Recruitment information / eligibility
Status Temporarily not available
Enrollment 0
Est. completion date
Est. primary completion date
Accepts healthy volunteers
Gender Female
Age group 18 Years and older
Eligibility

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Everolimus
mTOR inhibitor

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
The University of Texas Health Science Center at San Antonio
See also
  Status Clinical Trial Phase
Recruiting NCT04933669 - Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors Phase 2
Completed NCT01769248 - Prospective Trial of EUS-FNA Versus EUS-FNB Using a Novel Core Biopsy Needle N/A
Completed NCT01774162 - EUS-guided Fine Needle Biopsy With a New Core Histology Needle Versus Conventional Fine Needle Aspiration N/A
Completed NCT01110668 - Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST) Phase 2
Terminated NCT00091078 - Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery Phase 2
Completed NCT00025246 - Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery Phase 2
Active, not recruiting NCT00265798 - Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate Phase 2
Recruiting NCT04143048 - A Study on Non-invasive Early Diagnosis of Gastrointestinal Stromal Tumors and Differentiation of Benign and Malignant Nodules
Recruiting NCT02931981 - Serum Dickkopf-4 as a Biomarker for the Diagnosis and Treatment of Gastrointestinal Stromal Tumor N/A
Not yet recruiting NCT02576080 - Efficacy of Imatinib in Patients With Intermediate-risk Gastrointestinal Stromal Tumor With a High-risk Genomic Grade Index Phase 3
Recruiting NCT01389583 - A Study of AUY922 for GIST(Gastrointestinal Stromal Tumor) Patients Phase 2
Recruiting NCT00777504 - Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Phase 4
Completed NCT00769782 - Surgery in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor Phase 2
Completed NCT00764595 - Imatinib Mesylate in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor Phase 2
Completed NCT00098579 - Doxorubicin Hydrochloride and Alvocidib in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery Phase 1
Completed NCT00005862 - SU5416 in Treating Patients With Advanced, Metastatic, or Recurrent Soft Tissue Sarcomas Phase 2
Completed NCT00004895 - Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery Phase 2
Recruiting NCT02776878 - A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST N/A
Completed NCT01751919 - A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I) Phase 1
Completed NCT01267695 - Perioperative Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor Phase 2